Giles F J, Singer C R, Gray A G, Yong K L, Brozovic M, Davies S C, Grant I R, Hoffbrand A V, Machin S J, Mehta A B
Department of Haematology, University College Hospital, London.
Lancet. 1988 Jul 9;2(8602):70-2. doi: 10.1016/s0140-6736(88)90005-0.
18 patients with symptomatic essential thrombocythaemia were treated with recombinant alpha interferon (2a or 2b). Subcutaneous dosage regimens, which were well-tolerated, selectively lowered the platelet count and relieved symptoms in all patients, whether previously treated or untreated. Recombinant alpha-interferon may offer a non-leukaemogenic alternative therapy for these patients.
